Leonie R van der Werf1,2, Elske Marra3, Suzanne S Gisbertz4, Bas P L Wijnhoven5, Mark I van Berge Henegouwen4. 1. Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. l.r.vdwerf@gmail.com. 2. Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands. l.r.vdwerf@gmail.com. 3. Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, The Netherlands. 4. Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. 5. Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
BACKGROUND: Previous studies evaluating the association of lymph node (LN) yield and survival presented conflicting results and many may be influenced by confounding and stage migration. OBJECTIVE: This study aimed to evaluate whether the quality indicator 'retrieval of at least 15 LNs' is associated with better long-term survival and more accurate pathological staging in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy and resection. METHODS: Data of esophageal cancer patients who underwent neoadjuvant chemoradiotherapy and surgery between 2011 and 2016 were retrieved from the Dutch Upper Gastrointestinal Cancer Audit. Patients with < 15 and ≥ 15 LNs were compared after propensity score matching based on patient and tumor characteristics. The primary endpoint was 3-year survival. To evaluate the effect of LN yield on the accuracy of pathological staging, pathological N stage was evaluated and 3-year survival was analyzed in a subgroup of patients with node-negative disease. RESULTS: In 2260 of 3281 patients (67%) ≥ 15 LNs were retrieved. In total, 992 patients with ≥ 15 LNs were matched to 992 patients with < 15 LNs. The 3-year survival did not differ between the two groups (57% vs. 54%; p = 0.28). pN+ was scored in 41% of patients with ≥ 15 LNs versus 35% of patients with < 15 LNs. For node-negative patients, the 3-year survival was significantly better for patients with ≥ 15 LNs (69% vs. 61%, p = 0.01). CONCLUSIONS: n this propensity score-matched cohort, 3-year survival was comparable for patients with ≥ 15 LNs, although increasing nodal yield was associated with more accurate staging. In node-negative patients, 3-year survival was higher for patients with ≥ 15 LNs.
BACKGROUND: Previous studies evaluating the association of lymph node (LN) yield and survival presented conflicting results and many may be influenced by confounding and stage migration. OBJECTIVE: This study aimed to evaluate whether the quality indicator 'retrieval of at least 15 LNs' is associated with better long-term survival and more accurate pathological staging in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy and resection. METHODS: Data of esophageal cancerpatients who underwent neoadjuvant chemoradiotherapy and surgery between 2011 and 2016 were retrieved from the Dutch Upper Gastrointestinal Cancer Audit. Patients with < 15 and ≥ 15 LNs were compared after propensity score matching based on patient and tumor characteristics. The primary endpoint was 3-year survival. To evaluate the effect of LN yield on the accuracy of pathological staging, pathological N stage was evaluated and 3-year survival was analyzed in a subgroup of patients with node-negative disease. RESULTS: In 2260 of 3281 patients (67%) ≥ 15 LNs were retrieved. In total, 992 patients with ≥ 15 LNs were matched to 992 patients with < 15 LNs. The 3-year survival did not differ between the two groups (57% vs. 54%; p = 0.28). pN+ was scored in 41% of patients with ≥ 15 LNs versus 35% of patients with < 15 LNs. For node-negative patients, the 3-year survival was significantly better for patients with ≥ 15 LNs (69% vs. 61%, p = 0.01). CONCLUSIONS: n this propensity score-matched cohort, 3-year survival was comparable for patients with ≥ 15 LNs, although increasing nodal yield was associated with more accurate staging. In node-negative patients, 3-year survival was higher for patients with ≥ 15 LNs.
Authors: L A D Busweiler; B P L Wijnhoven; M I van Berge Henegouwen; D Henneman; N C T van Grieken; M W J M Wouters; R van Hillegersberg; J W van Sandick Journal: Br J Surg Date: 2016-10-05 Impact factor: 6.939
Authors: Ben M Eyck; Barbera D Onstenk; Bo J Noordman; Daan Nieboer; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot Journal: Ann Surg Date: 2020-02 Impact factor: 12.969
Authors: Leonie R van der Werf; Bas P L Wijnhoven; Laura F C Fransen; Johanna W van Sandick; Grard A P Nieuwenhuijzen; Linde A D Busweiler; Richard van Hillegersberg; Michel W J M Wouters; Misha D P Luyer; Mark I van Berge Henegouwen Journal: Ann Surg Date: 2019-11 Impact factor: 12.969
Authors: Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245
Authors: L R van der Werf; J L Dikken; M I van Berge Henegouwen; V E P P Lemmens; G A P Nieuwenhuijzen; B P L Wijnhoven Journal: Ann Surg Oncol Date: 2018-03-09 Impact factor: 5.344
Authors: Eliza R C Hagens; Mark I van Berge Henegouwen; Johanna W van Sandick; Miguel A Cuesta; Donald L van der Peet; Joos Heisterkamp; Grard A P Nieuwenhuijzen; Camiel Rosman; Joris J G Scheepers; Meindert N Sosef; Richard van Hillegersberg; Sjoerd M Lagarde; Magnus Nilsson; Jari Räsänen; Philippe Nafteux; Piet Pattyn; Arnulf H Hölscher; Wolfgang Schröder; Paul M Schneider; Christophe Mariette; Carlo Castoro; Luigi Bonavina; Riccardo Rosati; Giovanni de Manzoni; Sandro Mattioli; Josep Roig Garcia; Manuel Pera; Michael Griffin; Paul Wilkerson; M Asif Chaudry; Bruno Sgromo; Olga Tucker; Edward Cheong; Krishna Moorthy; Thomas N Walsh; John Reynolds; Yuji Tachimori; Haruhiro Inoue; Hisahiro Matsubara; Shin-Ichi Kosugi; Haiquan Chen; Simon Y K Law; C S Pramesh; Shailesh P Puntambekar; Sudish Murthy; Philip Linden; Wayne L Hofstetter; Madhan K Kuppusamy; K Robert Shen; Gail E Darling; Flávio D Sabino; Peter P Grimminger; Sybren L Meijer; Jacques J G H M Bergman; Maarten C C M Hulshof; Hanneke W M van Laarhoven; Banafsche Mearadji; Roel J Bennink; Jouke T Annema; Marcel G W Dijkgraaf; Suzanne S Gisbertz Journal: BMC Cancer Date: 2019-07-04 Impact factor: 4.430